<DOC>
	<DOCNO>NCT00876382</DOCNO>
	<brief_summary>A retrospective medical record abstraction study least 200 advanced renal cell carcinoma patient treat following setting : - Patients advance renal cell carcinoma treat Sorafenib ( Nexavar ) second-line therapy Sunitinib ( Sutent ) Bevacizumab ( Avastin ) first-line therapy ( 100 patient ) - Patients advance renal cell carcinoma treat Sorafenib ( Nexavar ) first-line therapy follow Sunitinib ( Sutent ) second-line therapy ( 100 patient )</brief_summary>
	<brief_title>Community Oncology Setting Disease Outcomes Sorafenib ( Nexavar ) Use Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description>Recently , number target agent demonstrate single-agent activity treatment advance renal cell carcinoma . Bevacizumab , humanize monoclonal antibody direct VEGF , result improvement median progression-free survival compare placebo prospective , randomized trial . More recently , multitargeted agent sorafenib sunitinib approve use treatment advance renal cell carcinoma . Both proven superior previous interferon standard treatment ; however clear drug use treatment sequence . With roughly 80 % cancer patient receive oncology care community setting , propose review evaluation least 200 advanced renal cell carcinoma patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Eligible patient case receive Sorafenib ( Nexavar ) secondline therapy Sunitinib ( Sutent ) Bevacizumab ( Avastin ) firstline therapy patient treat Sorafenib ( Nexavar ) firstline therapy follow Sunitinib ( Sutent ) secondline therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>advanced renal cell carcinoma</keyword>
	<keyword>renal cancer</keyword>
	<keyword>renal cell</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Sutent</keyword>
</DOC>